Corporate Responsibility Report

The report presents a 2023 CSR program centered on patient-focused antibody innovation and responsible operations. The company grew to 2,204 team members and achieved an 83% engagement score. It completed its first full Scope 1, 2 and 3 carbon footprint assessment and set a 42% Scope 1 and 2 reduction target for 2030. It also reported EU Taxonomy activity, including no eligible turnover or operating expenses and eligible capital expenditure.